Dual drug-loaded nanoparticles on self-integrated scaffold for controlled delivery.
Antioxidant (quercetin) and hypoglycemic (voglibose) drug-loaded poly-D,L-lactideco-glycolide nanoparticles were successfully synthesized using the solvent evaporation method. The dual drug-loaded nanoparticles were incorporated into a scaffold film using a solvent casting method, creating a controlled transdermal drug-delivery system. Key features of the film formulation were achieved utilizing several ratios of excipients, including polyvinyl alcohol, polyethylene glycol, hyaluronic acid, xylitol, and alginate. The scaffold film showed superior encapsulation capability and swelling properties, with various potential applications, eg, the treatment of diabetes-associated complications. Structural and light scattering characterization confirmed a spherical shape and a mean particle size distribution of 41.3 nm for nanoparticles in the scaffold film. Spectroscopy revealed a stable polymer structure before and after encapsulation. The thermoresponsive swelling properties of the film were evaluated according to temperature and pH. Scaffold films incorporating dual drug-loaded nanoparticles showed remarkably high thermoresponsivity, cell compatibility, and ex vivo drug-release behavior. In addition, the hybrid film formulation showed enhanced cell adhesion and proliferation. These dual drug-loaded nanoparticles incorporated into a scaffold film may be promising for development into a transdermal drug-delivery system.
Department of Bionanotechnology, Gachon University, Gyeonggi, Republic of Korea.
Devasier
D
Bennet
Mohana
M
Marimuthu
Sanghyo
S
Kim
Jeongho
J
An
D000328:Adult; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D002460:Cell Line; D003692:Delayed-Action Preparations; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007294:Inositol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry* / Q000648:ultrastructure; D049329:Nanostructures / Q000008:administration & dosage / Q000737:chemistry / Q000648:ultrastructure; D019301:Oleic Acid / Q000737:chemistry; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011794:Quercetin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D012869:Skin Absorption; D013696:Temperature
D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019301:Oleic Acid; D019344:Lactic Acid; D007294:Inositol; D011794:Quercetin; C102817:voglibose